Literature DB >> 25179732

Relapse of BCR-ABL1-like ALL mediated by the ABL1 kinase domain mutation T315I following initial response to dasatinib treatment.

D T Yeung1, D J Moulton2, S L Heatley3, E Nievergall3, P Dang3, J Braley4, S Branford4, S Moore4, C G Mullighan5, T P Hughes2, D L White6.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25179732     DOI： 10.1038/leu.2014.256

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  15 in total

1.  T315I mutation in Ph-positive acute lymphoblastic leukemia is associated with a highly aggressive disease phenotype: three case reports.

Authors:  Keisuke Watanabe; Yosuke Minami; Yukiyasu Ozawa; Koichi Miyamura; Tomoki Naoe
Journal:  Anticancer Res       Date:  2012-05       Impact factor: 2.480

2.  Tyrosine kinase inhibitor therapy induces remission in a patient with refractory EBF1-PDGFRB-positive acute lymphoblastic leukemia.

Authors:  Brent W Weston; Melissa A Hayden; Kathryn G Roberts; Susan Bowyer; Johann Hsu; George Fedoriw; Kathleen W Rao; Charles G Mullighan
Journal:  J Clin Oncol       Date:  2013-07-08       Impact factor: 44.544

Review 3.  The molecular genetic makeup of acute lymphoblastic leukemia.

Authors:  Charles G Mullighan
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2012

Review 4.  Seeking the causes and solutions to imatinib-resistance in chronic myeloid leukemia.

Authors:  D Bixby; M Talpaz
Journal:  Leukemia       Date:  2010-11-19       Impact factor: 11.528

5.  Tyrosine kinome sequencing of pediatric acute lymphoblastic leukemia: a report from the Children's Oncology Group TARGET Project.

Authors:  Mignon L Loh; Jinghui Zhang; Richard C Harvey; Kathryn Roberts; Debbie Payne-Turner; Huining Kang; Gang Wu; Xiang Chen; Jared Becksfort; Michael Edmonson; Kenneth H Buetow; William L Carroll; I-Ming Chen; Brent Wood; Michael J Borowitz; Meenakshi Devidas; Daniela S Gerhard; Paul Bowman; Eric Larsen; Naomi Winick; Elizabeth Raetz; Malcolm Smith; James R Downing; Cheryl L Willman; Charles G Mullighan; Stephen P Hunger
Journal:  Blood       Date:  2012-12-04       Impact factor: 22.113

6.  A subtype of childhood acute lymphoblastic leukaemia with poor treatment outcome: a genome-wide classification study.

Authors:  Monique L Den Boer; Marjon van Slegtenhorst; Renée X De Menezes; Meyling H Cheok; Jessica G C A M Buijs-Gladdines; Susan T C J M Peters; Laura J C M Van Zutven; H Berna Beverloo; Peter J Van der Spek; Gaby Escherich; Martin A Horstmann; Gritta E Janka-Schaub; Willem A Kamps; William E Evans; Rob Pieters
Journal:  Lancet Oncol       Date:  2009-01-08       Impact factor: 41.316

Review 7.  Part I: mechanisms of resistance to imatinib in chronic myeloid leukaemia.

Authors:  Jane F Apperley
Journal:  Lancet Oncol       Date:  2007-11       Impact factor: 41.316

8.  A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias.

Authors:  J E Cortes; D-W Kim; J Pinilla-Ibarz; P le Coutre; R Paquette; C Chuah; F E Nicolini; J F Apperley; H J Khoury; M Talpaz; J DiPersio; D J DeAngelo; E Abruzzese; D Rea; M Baccarani; M C Müller; C Gambacorti-Passerini; S Wong; S Lustgarten; V M Rivera; T Clackson; C D Turner; F G Haluska; F Guilhot; M W Deininger; A Hochhaus; T Hughes; J M Goldman; N P Shah; H Kantarjian
Journal:  N Engl J Med       Date:  2013-11-01       Impact factor: 91.245

9.  UKALLXII/ECOG2993: addition of imatinib to a standard treatment regimen enhances long-term outcomes in Philadelphia positive acute lymphoblastic leukemia.

Authors:  Adele K Fielding; Jacob M Rowe; Georgina Buck; Letizia Foroni; Gareth Gerrard; Mark R Litzow; Hillard Lazarus; Selina M Luger; David I Marks; Andrew K McMillan; Anthony V Moorman; Bella Patel; Elisabeth Paietta; Martin S Tallman; Anthony H Goldstone
Journal:  Blood       Date:  2013-11-25       Impact factor: 22.113

10.  Sensitive detection of BCR-ABL1 mutations in patients with chronic myeloid leukemia after imatinib resistance is predictive of outcome during subsequent therapy.

Authors:  Wendy T Parker; Rebecca M Lawrence; Musei Ho; Darryl L Irwin; Hamish S Scott; Timothy P Hughes; Susan Branford
Journal:  J Clin Oncol       Date:  2011-10-11       Impact factor: 44.544
View more
  9 in total

Review 1.  Philadelphia Chromosome-like Acute Lymphoblastic Leukemia.

Authors:  Ching-Hon Pui; Kathryn G Roberts; Jun J Yang; Charles G Mullighan
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2017-08

2.  Acute Sensitivity of Ph-like Acute Lymphoblastic Leukemia to the SMAC-Mimetic Birinapant.

Authors:  Jennifer Richmond; Alissa Robbins; Kathryn Evans; Dominik Beck; Raushan T Kurmasheva; Catherine A Billups; Hernan Carol; Sue Heatley; Rosemary Sutton; Glenn M Marshall; Deborah White; John Pimanda; Peter J Houghton; Malcolm A Smith; Richard B Lock
Journal:  Cancer Res       Date:  2016-06-14       Impact factor: 12.701

Review 3.  Ph-like acute lymphoblastic leukemia.

Authors:  Thai Hoa Tran; Mignon L Loh
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2016-12-02

Review 4.  Has Ph-like ALL Superseded Ph+ ALL as the Least Favorable Subtype?

Authors:  Thai Hoa Tran; Sarah K Tasian
Journal:  Best Pract Res Clin Haematol       Date:  2021-10-23       Impact factor: 3.020

5.  Characterization of leukemias with ETV6-ABL1 fusion.

Authors:  Marketa Zaliova; Anthony V Moorman; Giovanni Cazzaniga; Martin Stanulla; Richard C Harvey; Kathryn G Roberts; Sue L Heatley; Mignon L Loh; Marina Konopleva; I-Ming Chen; Olga Zimmermannova; Claire Schwab; Owen Smith; Marie-Joelle Mozziconacci; Christian Chabannon; Myungshin Kim; J H Frederik Falkenburg; Alice Norton; Karen Marshall; Oskar A Haas; Julia Starkova; Jan Stuchly; Stephen P Hunger; Deborah White; Charles G Mullighan; Cheryl L Willman; Jan Stary; Jan Trka; Jan Zuna
Journal:  Haematologica       Date:  2016-05-26       Impact factor: 9.941

6.  Transposon-mediated generation of BCR-ABL1-expressing transgenic cell lines for unbiased sensitivity testing of tyrosine kinase inhibitors.

Authors:  Konstantin Byrgazov; Chantal Blanche Lucini; Bettina Berkowitsch; Margit Koenig; Oskar A Haas; Gregor Hoermann; Peter Valent; Thomas Lion
Journal:  Oncotarget       Date:  2016-11-22

7.  An activating mutation of GNB1 is associated with resistance to tyrosine kinase inhibitors in ETV6-ABL1-positive leukemia.

Authors:  O Zimmermannova; E Doktorova; J Stuchly; V Kanderova; D Kuzilkova; H Strnad; J Starkova; M Alberich-Jorda; J H F Falkenburg; J Trka; J Petrak; J Zuna; M Zaliova
Journal:  Oncogene       Date:  2017-06-26       Impact factor: 9.867

Review 8.  New biological and genetic classification and therapeutically relevant categories in childhood B-cell precursor acute lymphoblastic leukemia.

Authors:  Jan Starý; Jan Zuna; Marketa Zaliova
Journal:  F1000Res       Date:  2018-09-28

Review 9.  How I diagnose and manage Philadelphia chromosome-like acute lymphoblastic leukemia.

Authors:  Avraham Frisch; Yishai Ofran
Journal:  Haematologica       Date:  2019-10-03       Impact factor: 9.941
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.